Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

7.7%

1 terminated/withdrawn out of 13 trials

Success Rate

90.9%

+4.4% vs industry average

Late-Stage Pipeline

77%

10 trials in Phase 3/4

Results Transparency

80%

8 of 10 completed trials have results

Key Signals

1 recruiting8 with results

Enrollment Performance

Analytics

Phase 3
10(76.9%)
Phase 1
3(23.1%)
13Total
Phase 3(10)
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (13)

Showing 13 of 13 trials
NCT03747458Phase 3Active Not Recruiting

OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps

Role: lead

NCT06850805Phase 3Recruiting

Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps

Role: lead

NCT03781804Phase 3Completed

Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps

Role: lead

NCT03960580Phase 3Completed

Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis Without the Presence of Nasal Polyps

Role: lead

NCT05035576Phase 1Terminated

A Study to Evaluate Change in Viral Load After OPN-019 in Adults With COVID-19

Role: lead

NCT03591068Phase 3Completed

Efficacy & Safety of OPN-375 Adults With Bilateral Nasal Polyps Using Nasoendoscopic Video

Role: lead

NCT01622569Phase 3Completed

Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety

Role: lead

NCT01624662Phase 3Completed

Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Using a Novel Bi-directional Device

Role: lead

NCT01623310Phase 3Completed

12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device

Role: lead

NCT01623323Phase 3Completed

Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps

Role: lead

NCT02266927Phase 1Completed

A Study to Compare the Bioavailability Intranasal Administration of 200 and 400 µg or 400 µg Alone of OPTINOSE™ FLUTICASONE With 440 µg of Flovent® HFA (Fluticasone Propionate) Inhalation Aerosol (Part 2)

Role: lead

NCT01462812Phase 3Completed

Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine

Role: lead

NCT01507610Phase 1Completed

Bioavailability Study to Compare OPTINOSE SUMATRIPTAN With IMITREX® in Healthy Subjects

Role: lead

All 13 trials loaded